ROMIPLOSTIM and DEATH

Overview

DEATH is the #4 most commonly reported adverse reaction for ROMIPLOSTIM, manufactured by Amgen, Inc. There are 989 FDA adverse event reports linking ROMIPLOSTIM to DEATH. This represents approximately 4.1% of all 24,148 adverse event reports for this drug.

Patients taking ROMIPLOSTIM who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is moderately reported among ROMIPLOSTIM users, representing a notable but not dominant share of adverse events.

Other Side Effects of ROMIPLOSTIM

In addition to death, the following adverse reactions have been reported for ROMIPLOSTIM:

• DRUG INEFFECTIVE — 1,700 reports
• PLATELET COUNT DECREASED — 1,689 reports
• OFF LABEL USE — 1,164 reports
• THERAPEUTIC RESPONSE DECREASED — 942 reports
• PLATELET COUNT ABNORMAL — 939 reports
• THROMBOCYTOPENIA — 930 reports
• HEADACHE — 582 reports
• FATIGUE — 455 reports
• HAEMORRHAGE — 374 reports
• PLATELET COUNT INCREASED — 373 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does ROMIPLOSTIM cause DEATH?

DEATH has been reported as an adverse event in 989 FDA reports for ROMIPLOSTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with ROMIPLOSTIM?

DEATH accounts for approximately 4.1% of all adverse event reports for ROMIPLOSTIM, making it a notable side effect.

What should I do if I experience DEATH while taking ROMIPLOSTIM?

If you experience death while taking ROMIPLOSTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages